PSMB9 and experimental autoimmune encephalomyelitis: Specifically, the combined inhibition of LMP7 and LMP2, using the selective LMP7 inhibitor PRN1126 alongside LMP2 inhibitors, such as LU-001i or ML604440, was shown to reduce MHC-I surface expression on splenocytes, suppress IL-6 secretion, impair Th17 differentiation, and alleviate symptoms in models of experimental colitis and experimental autoimmune encephalomyelitis (EAE) [163].